NICE Urges Annual PMOS Reviews for 1 in 8 Women as Draft Seeks Earlier Diagnosis
Updated
Updated · WiredGov · Jul 2
NICE Urges Annual PMOS Reviews for 1 in 8 Women as Draft Seeks Earlier Diagnosis
3 articles · Updated · WiredGov · Jul 2
Summary
NICE's draft PMOS guideline calls for yearly reviews covering symptoms, medicines and risks such as diabetes and cardiovascular disease, aiming to catch complications earlier in a condition affecting about 1 in 8 women.
The draft also pushes faster diagnosis, saying people with irregular or absent periods plus signs of excess male hormones should be investigated, and that PMOS should not be ruled out after menopause.
Mental health, eating disorders, fertility care and common symptoms including acne, hirsutism and sleep apnoea are all addressed, with IVF recommended for eligible patients under existing fertility rules.
NICE declined to recommend laser and light hair-reduction therapies, estimating they could cost the NHS up to £100 million a year in England without being cost-effective.
Public consultation runs from July 1 to August 11, with NICE expecting to publish the final UK-focused guideline in December 2026.
Could off-label weight-loss drugs soon become the standard NHS treatment for PMOS, despite current guidelines?
Why won't the NHS fund a £100m treatment for a key PMOS symptom if it severely impacts mental health?
Major Overhaul in PMOS (Formerly PCOS) Care: What the 2026 NICE Guidelines Mean for Patients and the NHS
Overview
The new draft guidelines from NICE, published in July 2026, mark a major shift in the diagnosis and treatment of Polyendocrine Metabolic Ovarian Syndrome (PMOS) across the UK. By introducing a simple annual review for those with PMOS, the guidelines aim to standardize care, improve consistency, and boost awareness of the condition. This proactive approach supports earlier diagnosis and better management, addressing both immediate symptoms and long-term health risks. The emphasis on regular monitoring and early intervention is expected to improve patient outcomes and ensure more equitable, effective care nationwide.